Amgen 2012 Annual Report Download - page 147

Download and view the complete annual report

Please find page 147 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

F-48
19. Segment information
We operate in one business segment — human therapeutics. Therefore, results of our operations are reported on a consolidated
basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product
sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below.
Revenues
Revenues were as follows for the years ended December 31, 2012, 2011 and 2010 (in millions):
2012 2011 2010
Product sales:
Neulasta® $ 4,092 $ 3,952 $ 3,558
NEUPOGEN® 1,260 1,260 1,286
ENBREL 4,236 3,701 3,534
Aranesp® 2,040 2,303 2,486
EPOGEN® 1,941 2,040 2,524
Sensipar®/Mimpara®950 808 714
Vectibix® 359 322 288
Nplate® 368 297 229
XGEVA® 748 351 8
Prolia® 472 203 33
Other 173 58 —
Total product sales 16,639 15,295 14,660
Other revenues 626 287 393
Total revenues $ 17,265 $ 15,582 $ 15,053
Geographic information
Outside the United States, we sell products principally in Europe and Canada. The geographic classification of product sales
was based on the location of the customer. The geographic classification of all other revenues was based on the domicile of the
entity from which the revenues were earned.
Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment)
was as follows (in millions):
Years ended December 31,
2012 2011 2010
Revenues:
United States $ 13,415 $ 11,985 $ 11,636
ROW 3,850 3,597 3,417
Total revenues $ 17,265 $ 15,582 $ 15,053
December 31,
2012 2011
Long-lived assets:
United States $ 2,906 $ 3,144
Puerto Rico 1,908 1,993
ROW 512 283
Total long-lived assets $ 5,326 $ 5,420